Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.53 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8875999 | 0.81 | HTR6 (0.53) | HTR6HTR1BCHRM2HTR1AADRA2A | |
| SCHEMBL1067210 | 0.81 | CHRM2 (0.64) | HTR6HTR1BCHRM2HTR1AADRA2A | |
| SCHEMBL1067208 | 0.81 | CHRM2 (0.64) | HTR6HTR1BCHRM2HTR1AADRA2A | |
| SCHEMBL7079772 | 0.81 | HTR6 (0.53) | HTR6HTR1BCHRM2HTR1AADRA2A | |
| SCHEMBL722273 | 0.80 | HTR6 (0.54) | HTR6HTR1BCHRM2HTR1AADRA2A | |
| SCHEMBL1697440 | 0.80 | HTR6 (0.54) | HTR6HTR1BCHRM2HTR1AADRA2A | |
| SCHEMBL773348 | 0.80 | HTR6 (0.54) | HTR6HTR1BCHRM2HTR1AADRA2A | |
| SCHEMBL774709 | 0.80 | HTR6 (0.54) | HTR6HTR1BCHRM2HTR1AADRA2A | |
| SCHEMBL8789709 | 0.78 | HTR1B (0.70) | HTR6HTR1BHTR1DCHRM2HTR1A | |
| SCHEMBL2180885 | 0.77 | HTR6 (0.46) | HTR6HTR1BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373254-B1 | Process for the preparation of the anti-migraine drug eletriptan | PFIZER LTD (GB) | 2005-11-02 | — | — | EP | disclosed |
| US-20030166704-A1 | New process | PFIZER INC. | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166704-A1 | New process | TFPI, HTR4, HTR5A | HTR6 20/4885HTR1B 32/4885HTR1D 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.